## PRIOR AUTHORIZATION PROGRAM REIMBURSEMENT REQUEST FORM For cancer therapy: Stivarga (regorafenib)

Please fax form to: 1-866-840-1509

Please note that the patient AND physician must complete this form. All fields are mandatory and must be completed. Incomplete forms may result in your application being declined. Please retain a copy of this form for your records.

## Instructions:

- 1. PLEASE PRINT CLEARLY AND COMPLETE ALL SECTIONS.
- 2. The patient/plan member must complete section A.
- **3.** Your physician must complete section B. The cost, if any, of completing this form is at the expense of the patient/plan member.
- **4.** Please return the form to your insurance company via Pharmacy Services at TELUS Health (a service provider of your insurance company) by fax to **1-866-840-1509**.
- 5. If you have any questions on the application of this program or the decision on reimbursement, or to inquire on the status of your Reimbursement Request Form, please contact your insurer.

A. Information to be Completed by Patient								
Employee or Insured's Name	Drug Card Number							
Patient's Name	Patient's Date of Birth (DD/MM/YYYY)	Relationship to Employee/Insured						
	//	□Employee □Spouse □Dependent						
Please allow two business days for a response once all information is received and complete.  Notification of the results of this request will occur Monday to Friday between 9 am and 4 pm Eastern Time.								
Please provide contact information and indicate <b>ONE</b> method of preferred contact for notification of the results:								
☐ E-mail	Call me (and leave a message if I'm not there)							
Contact my pharmacy: Pharmacy Name		Pharmacy Phone Number						
I certify that the information provided by me is true, correct and complete to the best of my knowledge. I authorize my insurance company, TELUS Health (a service provider of my insurance company), their authorized representatives, agents and service providers to use and exchange this information needed for underwriting, administration and paying claims with any person or organization who has relevant information pertaining to this claim including health professionals, institutions and investigative agencies in the event of an audit. I authorize my insurance company and/or TELUS Health (a service provider of my insurance company) to contact any licensed physician, institution, pharmacy or person who has any records or knowledge of me or my health with respect to this submitted claim.								
SIGNATURE OF PATIENT/PARENT/LEGAL GUARDIAN								
Date: (DD/MM/YYYY):/								

## PRIOR AUTHORIZATION PROGRAM REIMBURSEMENT REQUEST FORM For cancer therapy: Stivarga (regorafenib)

Please fax form to: 1-866-840-1509

B. Information to be Completed by Prescribing	Pnysician				
Drug Name	Strength	Dose			
Stivarga (regorafenib)					
Stivarga (regorafenib) will be eligible for reimbursembelow and if the patient does not qualify for coverage program. If the patient is covered under another drug plauthorization program, as part of your drug benefits, may "None of the above criteria" is indicated, the patient will members, please refer to the RAMQ exception drug criteria.	under any other drug plan or g lan or government mandated pro y cover the portion not paid for l not be eligible for reimbursem	<b>povernment mandated</b> ogram, the prior by the primary plan. If			
Eligibility Criteria					
Please indicate if the patient satisfies the following criteria:	<u> </u>				
metastatic colorectal cancer (CRC) (781076008)  ☐ Prescriber is an oncologist or qualified physician with experiments all the following criteria: ☐ Physician confirms the patient meets the drug's patients with metastatic colorectal cancer (CRC based chemotherapy, oxaliplatin, irinotecan, an applicable)*; AND ☐ ECOG status ≤1;  OR	s Health Canada approved indicat C) who have been previously treat	ion for treatment of adult ed with fluoropyrimidine-			
metastatic and/or unresectable gastrointestinal stromal to  □ Prescriber is an oncologist or qualified physician with ex □ Patient meets all the following criteria: □ adult patients with metastatic and/or unresectatisease progression on or intolerance to imatini □ ECOG status ≤1;  OR	sperience in the use of anti-cance able gastrointestinal stromal tumo	our (GIST) who have had			
hepatocellular carcinoma (HCC) (109841003)  ☐ Prescriber is an oncologist or qualified physician with expension of the patient meets all the following criteria: ☐ Adult patients with hepatocellular carcinoma (House Barcelona Clinic Liver Cancer stage Category Beneficacy with higher priority such as resection, Liver function status Child-Pugh Class A; AND☐ ECOG status ≤1.	HCC) who have been previously tro or C that cannot benefit from trea	eated with sorafenib; AND atments of established			
OR ☐ None of the above criteria applies.					
Relevant additional information					
*May also be subject to prior authorization					

## PRIOR AUTHORIZATION PROGRAM REIMBURSEMENT REQUEST FORM For cancer therapy: Stivarga (regorafenib)

Please fax form to: 1-866-840-1509

Physician Information									
Physician's Name	License Number	Telephone Number		Fax Number					
Address		City	Province	1	Postal Code				
Physician's Signature		Date: (DD/MM/YYYY)							
		//							